PROFILPELAJAR.COM

Glecirasib

Glecirasib
Clinical data
Drug classKRAS G12C inhibitor
Legal status
Legal status
  • Rx in China
Identifiers
  • (1M)-7-(2-Amino-3,4,5,6-tetrafluorophenyl)-6-chloro-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-2-oxo-4-[4-(prop-2-enoyl)piperazin-1-yl]-1,2-dihydro-1,8- naphthyridine-3-carbonitrile
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC31H26ClF4N7O2
Molar mass640.04 g·mol−1
3D model (JSmol)
  • CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C(=C(C(=C5F)F)F)F)N
  • InChI=1S/C31H26ClF4N7O2/c1-5-19(44)41-8-10-42(11-9-41)29-16-12-18(32)27(20-21(33)22(34)23(35)24(36)25(20)38)40-30(16)43(31(45)17(29)13-37)28-15(4)6-7-39-26(28)14(2)3/h5-7,12,14H,1,8-11,38H2,2-4H3
  • Key:QRRJEUIQLZNPIO-UHFFFAOYSA-N

Glecirasib (JAB-21822) is a pharmaceutical drug used for cancer treatment. It is a selective inhibitor of the G12C mutant version of the enzyme KRAS. It is used as a combination treatment alongside other selective enzyme inhibitors.[1][2][3][4]

References

  1. ^ Shi Y, Fang J, Xing L, Yao Y, Zhang J, Liu L, et al. (March 2025). "Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial". Nature Medicine. 31 (3): 894–900. doi:10.1038/s41591-024-03401-z. PMID 39762419.
  2. ^ Dong P, Ni J, Zheng X, Wang M, Yang M, Han H (June 2025). "Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future". European Journal of Pharmacology. 996 177428. doi:10.1016/j.ejphar.2025.177428. PMID 40024323.
  3. ^ Li J, Wang Z, Huang J, Ba Y, Cao B, Luo S, et al. (February 2026). "Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials". The Lancet. Gastroenterology & Hepatology. 11 (2): 110–123. doi:10.1016/S2468-1253(25)00267-5. PMID 41344351.
  4. ^ Li J, Deng T, Gu Y, Calles Blanco A, Li Z, Bai C, et al. (November 2025). "Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials". Cancer Communications. 45 (11): 1500–1512. doi:10.1002/cac2.70056. PMC 12629856. PMID 41037823.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.